• Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Get Email Updates
  • We’re hiring!
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Get Email Updates
  • We’re hiring!

Nigerian Institute of Medical Research – COVID-19 Fractional Dosing Trial

Visit Grantee Site
  • Focus Area: Biosecurity & Pandemic Preparedness
  • Organization Name: Nigerian Institute of Medical Research
  • Amount: $2,921,000

  • Award Date: January 2022

Table of Contents

    Open Philanthropy recommended a grant of $2,921,000 to the Nigerian Institute of Medical Research to support a safety and immunogenicity trial in adults in Nigeria of fractional doses of the AstraZeneca, Pfizer, and Johnson & Johnson COVID-19 vaccines. The trial has the potential to indicate that smaller doses of these vaccines promote immune responses that are “non-inferior” to those from standard doses. If non-inferiority can be established, this could allow many people to be vaccinated against COVID-19 sooner despite limited supplies, and potentially affect booster recommendations in Nigeria or elsewhere, reducing deaths and other harms from the pandemic.

    This falls within our work on scientific research, and specifically within our interest in science supporting biosecurity and pandemic preparedness.

    Related Items

    • Biosecurity & Pandemic Preparedness

      Berkeley Existential Risk Initiative — Support for Kevin Esvelt's Research

      Open Philanthropy recommended a grant of $100,000 to the Berkeley Existential Risk Initiative to provide support for Kevin Esvelt's Sculpting Evolution group at the MIT Media Lab. This falls within...

      Read more
    • Biosecurity & Pandemic Preparedness

      Effective Altruism Foundation — European Policy Research and Advocacy (2022)

      Open Philanthropy recommended a grant of $200,000 to the Effective Altruism Foundation (EAF) to support research and advocacy on potential policy interventions in Europe. EAF plans to use...

      Read more
    • Biosecurity & Pandemic Preparedness

      1Day Sooner — General Support (2021)

      Open Philanthropy recommended a grant of $2,000,000 to 1Day Sooner for general support. 1Day Sooner’s mission is to advocate on behalf of volunteers for human challenge trials (HCTs)....

      Read more
    Back to Grants Database
    Open Philanthropy
    Open Philanthropy
    • Careers
    • Press Kit
    • Governance
    • Privacy Policy
    Mailing Address
    182 Howard Street #225
    San Francisco, CA 94105
    Email
    [email protected]
    Media Inquiries
    [email protected]
    Anonymous Feedback
    Feedback Form

    Sign Up to Follow Our Work

    Join Our Mailing List

    © Open Philanthropy 2022